Pic: via Getty Images.
Weed Week: Snoop Dogg releases Death Row Cannabis and Aussie player hits the German market
Health & Biotech
share
- Snoop Dogg acquires Death Row Official and releases new cannabis brand
- ECS Botanics signs $9.9m supply agreement for the German medicinal cannabis market
- Cann Group announces new CEO in Peter Koetsier
Recently acquired by Snoop Dogg, www.deathrowofficial.com has reemerged as a multi-category cultural platform across music, fashion, entertainment, and now…cannabis.
For those cannabis connoisseurs the man responsible for curating Death Row Cannabis, AK – hand-selected by Snoop himself – is a longtime West Coast legacy cultivator and industry insider, best known for his role alongside former partner WizardTrees in sprouting, selecting, and expertly growing the RS11, Studio 54, and Shirazi strains from exotic cannabis breeder DEO.
He’s the man behind the IYKYK brand SMKRS, and he is also well known as the VP of Cultivation for TRP LLC, who owns a majority of the Cookies stores across the nation including their facilities in Florida.
AK’s reputation for growing “fire” weed and his palette when it comes to selecting winning strains, keeps people camped out in lines in front of their dispensaries.
ASX WEED STOCKS
| Code | Company | Price | % Year | % Six Month | % Month | % Week | Market Cap |
|---|---|---|---|---|---|---|---|
| EOF | Ecofibre Limited | 0.265 | -54% | 15% | -7% | 15% | $87,303,638 |
| ECS | ECS Botanics Holding | 0.024 | -17% | -8% | 9% | 14% | $26,561,536 |
| BOT | Botanix Pharma Ltd | 0.058 | -3% | -17% | -3% | 12% | $73,623,826 |
| CPH | Creso Pharma Ltd | 0.022 | -73% | -46% | 10% | 10% | $41,554,024 |
| IHL | Incannex Healthcare | 0.1875 | -72% | -22% | 1% | 7% | $293,596,916 |
| EXL | Elixinol Wellness | 0.021 | -71% | -30% | -9% | 5% | $6,641,577 |
| WOA | Wide Open Agricultur | 0.21 | -70% | -63% | -21% | 5% | $27,044,172 |
| AGH | Althea Group | 0.064 | -72% | -20% | -2% | 3% | $23,128,254 |
| EMD | Emyria Limited | 0.17 | -56% | -24% | -13% | 3% | $49,444,383 |
| MDC | Medlab Clinical Ltd | 6.93 | -69% | -44% | 0% | 3% | $15,710,494 |
| LGP | Little Green Pharma | 0.18 | -71% | -40% | 6% | 3% | $45,661,135 |
| ZLD | Zelira Therapeutics | 1.01 | -82% | -30% | 1% | 1% | $9,625,002 |
| CAU | Cronos Australia | 0.6025 | 104% | 187% | -9% | 0% | $333,919,243 |
| CTV | Colortv Limited | 0.008 | -84% | 14% | 0% | 0% | $1,236,985 |
| HGV | Hygrovest Limited | 0.07 | 27% | 13% | -1% | 0% | $16,096,779 |
| SCU | Stemcell United Ltd | 0.013167 | 0% | 0% | 0% | 0% | $14,995,837 |
| MRG | Murray River Grp | 0.245 | 0% | 0% | 0% | 0% | $10,808,210 |
| CAN | Cann Group Ltd | 0.21 | -28% | -30% | -5% | 0% | $81,203,822 |
| RGI | Roto-Gro Intl Ltd | 0.22 | -48% | 0% | 0% | 0% | $4,333,920 |
| IRX | Inhalerx Limited | 0.06 | -40% | -20% | -8% | 0% | $11,236,017 |
| AVE | Avecho Biotech Ltd | 0.013 | -19% | 0% | 63% | 0% | $23,892,301 |
| AC8 | Auscann Grp Hlgs Ltd | 0.04 | -52% | -17% | 0% | 0% | $17,621,884 |
| EVE | EVE Health Group Ltd | 0.001 | -70% | 0% | 0% | 0% | $7,911,724 |
| CGB | Cann Global Limited | 0.021 | -58% | -13% | 0% | 0% | $5,436,345 |
| IDT | IDT Australia Ltd | 0.079 | -67% | -41% | -8% | -1% | $19,040,722 |
| NTI | Neurotech Intl | 0.07 | 25% | 0% | -10% | -1% | $58,938,818 |
| ALA | Arovella Therapeutic | 0.023 | -38% | -12% | -15% | -4% | $14,817,762 |
| RNO | Rhinomed Ltd | 0.11 | -62% | -12% | 5% | -4% | $31,429,166 |
| WFL | Wellfully Limited | 0.015 | -79% | -72% | -12% | -6% | $5,867,223 |
| EPN | Epsilon Healthcare | 0.023 | -63% | -32% | -8% | -8% | $7,208,496 |
| MXC | Mgc Pharmaceuticals | 0.011 | -77% | -42% | -8% | -8% | $34,390,168 |
| BOD | BOD Science Ltd | 0.13 | -40% | 48% | -19% | -13% | $20,671,402 |
| DTZ | Dotz Nano Ltd | 0.26 | -40% | -13% | 2% | -13% | $119,308,531 |
| LV1 | Live Verdure Ltd | 0.17 | -59% | -3% | -32% | -23% | $12,539,040 |
| ROO | Roots Sustainable | 0.0015 | -70% | -57% | -25% | -25% | $1,558,829 |
| TSN | The Sust Nutri Grp | 0.026 | -83% | -81% | -81% | -81% | $3,256,372 |
| PAL | Palla Pharma Ltd | 0 | -100% | -100% | -100% | -100% | $47,764,383 |
Only 12 companies were in the green, with 12 flat and 13 stocks in the red.
Here are the ones with notable news:
The company secured a $9.9m supply agreement into the German medicinal cannabis market with Ilios Santė Gmbh, part of the Bloomwell Group, which also includes Algea Care, Germany`s leading platform for therapy with medicinal cannabis.
ECS will exclusively supply four medicinal cannabis strains with a minimum revenue of $9.9m of GMP manufactured medicinal cannabis products over the next three years.
First supply is anticipated once product registration has been completed.
Meanwhile, the German medicinal cannabis market continues to grow strongly, with German legislators recently moving to legalise recreational use.
ÉCS’s Head of European Operations, Michael Clark, believes Germany provides a foot in the door for ECS to enter Europe.
“Securing an agreement with a long term partner in Germany was an essential building block of ECS`s EU market access strategy,” Clark said.
“This partnership enables ECS and Ilios Sante to grow an exciting and sustainable business together in Europe`s largest medicinal cannabis market.”
The cannabis company has announced that Peter Koetsier has been appointed to the role of CEO, and will commence on January 16, replacing Peter Crock, who announced his resignation in October.
Koetsier has more than 30 years of general management, marketing and commercial leadership roles within global pharmaceutical companies and was most recently been Head of Asia Pacific for French biopharmaceutical company, Ipsen.
“Peter is an experienced pharma industry executive with an established track record of driving strong revenue growth in complex and changing environments,” chairman Allan McCallum said.
“His experience and skills are ideally suited to the needs of Cann and to meeting the opportunities that continue to develop within the medicinal cannabis industry.”
The wellness brand and product manufacturer has recorded a 54% increase in revenue for H1 FY23 of $13.2 million (unaudited) compared to pcp of $8.6 million.
WNX reaffirms its previously announced guidance of $29 million for FY23 and anticipates revenue and margins to continue to accelerate for H2 FY23 through:
- Launch of Pharmacy Own in Q1 CY23–with first products to be available by the end of January 2023
- Medicinal cannabis products to be offered under the SAS-B scheme in Q1 CY2
- Continued growth of the new e-commerce brand and platform – TheSet
- Continued growth of WNX’s wholly owned brands and contract manufacturing orders
The increase in revenue of 54% is reflective of the strong growth across the whole business, but primarily growth in WNX’s wholly owned brands and contract manufacturing orders for its products.
Along with its Joint Venture (JV) partner OneLife Botanicals, the company is also progressing multiple medicinal cannabis products for the growing Special Access Market (SAS) – estimated to be worth over $400 million in 2022 – with a planned launch in the first quarter in FY23.
This rollout is expected to coincide with WNX’s over-the-counter Schedule 3 (S3) registration, which would allow products to be sold directly to consumers by a pharmacist without requiring a prescription.
ECS, CAN and WNX share prices today:
At Stockhead we tell it like it is. While Wellnex Life is a Stockhead advertiser, it did not sponsor this article.
